High risk HPV load estimated by Hybrid Capture II® correlates with HPV 16 load measured by real-time PCR in cervical smears of HPV 16-infected women

Journal of Clinical Virology

Volumn 31, Issue 2, 2004, Pages 140-147

  Prétet, Jean Luc ^a   Dalstein, Véronique ^a   Monnier Benoit, Sylvain ^a   Delpeut, Sébastien ^a   Mougin, Christiane ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Cervical cancer; cervical intraepithelial neoplasia; CIN; HCII; HGSIL; high grade squamous intraepithelial lesion; high risk; HPV; HR; human papillomavirus; Human papillomavirus; Hybrid Capture II; PC; positive control; relative light unit; RLU; Viral load

Indexed keywords

ALBUMIN; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; PAPILLOMA VIRUS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; REPRODUCIBILITY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VALIDATION PROCESS; VIRUS CULTURE; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD; WART VIRUS;

BASE SEQUENCE; DNA PROBES, HPV; DNA, VIRAL; FEMALE; HUMANS; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; VAGINAL SMEARS; VIROLOGY;

EID: 4444285036     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.02.008     Document Type: Article

References (34)

1. Bory J.P., Cucherousset J., Lorenzato M., Gabriel R., Quereux C., Birembaut P., et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int. J. Cancer. 102:2002;519-525
2. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer IBSCC Study Group. J. Natl. Cancer Inst. 87:1995;796-802
3. Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer. 84:2001;1616-1623
4. Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I., et al. HPV testing in primary screening of older women. Br. J. Cancer. 81:1999;554-558
5. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 362:2003;1871-1876
6. Dalstein V., Riethmuller D., Prétet J.L., Le Bail Carval K., Sautière J.L., Carbillet J.P., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer. 106:2003;396-403
7. Elfgren K., Jacobs M., Walboomers J.M., Meijer C.J., Dillner J., Kjaer S.K., et al. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Obstet. Gynecol. 100:2002;965-971
8. Farthing A., Masterson P., Mason W.P., Vousden K.H. Human papillomavirus detection by hybrid capture and its possible clinical use. J. Clin. Pathol. 47:1994;649-652
9. Gravitt P.E., Burk R.D., Lorincz A., Herrero R., Hildesheim A., Sherman M.E., et al. Comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol. Biomarkers Prev. 12:2003;477-484
10. Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87:1995;1365-1371
11. Jain S., Tseng C.J., Horng S.G., Soong Y.K., Pao C.C. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecol. Oncol. 82:2001;177-180
12. Josefsson A.M., Magnusson P.K., Ylitalo N., Sorensen P., Qwarforth-Tubbin P., Andersen P.K., et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet. 355:2000;2189-2193
13. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 325:2002;572
14. Laurendeau I., Bahuau M., Vodovar N., Larramendy C., Olivi M., Bieche I., et al. TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency. Clin. Chem. 45:1999;982-986
15. Lorincz A.T., Castle P.E., Sherman M.E., Scott D.R., Glass A.G., Wacholder S., et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 360:2002;228-229
16. Manos M., Ting Y., Wright D., Lewis A., Broker T., Wolinsky S. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells. 7:1989;209-214
17. Moberg M., Gustavsson I., Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J. Clin. Microbiol. 41:2003;3221-3228
18. Monsonego J., Bosch F.X., Coursaget P., Cox J.T., Franco E., Frazer I., et al. Cervical cancer control, priorities and new directions. Int. J. Cancer. 108:2004;329-333
19. Nobbenhuis M.A., Meijer C.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Risse E.K., et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br. J. Cancer. 84:2001;796-801
20. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 354:1999;20-25
21. Peitsaro P., Johansson B., Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J. Clin. Microbiol. 40:2002;886-891
22. Petry K.U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer. 88:2003;1570-1577
23. Rasmussen R, 2001. Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K, editors. Rapid cycle real-time PCR. Methods and applications, Springer. p. 21-34.
24. Riethmuller D., Gay C., Bertrand X., Bettinger D., Schaal J.P., Carbillet J.P., et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn. Mol. Pathol. 8:1999;157-164
25. Rousseau M.C., Pereira J.S., Prado J.C., Villa L.L., Rohan T.E., Franco E.L. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J. Infect. Dis. 184:2001;1508-1517
26. Sun C.A., Lai H.C., Chang C.C., Neih S., Yu C.P., Chu T.Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol. Oncol. 83:2001;95-99
27. Sun C.A., Liu J.F., Wu D.M., Nieh S., Yu C.P., Chu T.Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int. J. Gynaecol. Obstet. 76:2002;41-47
28. Sun X.W., Ferenczy A., Johnson D., Koulos J.P., Lungu O., Richart R.M., et al. Evaluation of the Hybrid Capture human papillomavirus deoxyribonucleic acid detection test. Am. J. Obstet. Gynecol. 173:1995;1432-1437
29. The ALTS Group, 2000. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92:397-402.
30. Trofatter K.F. Jr. Diagnosis of human papillomavirus genital tract infection. Am. J. Med. 102:1997;21-27
31. van Duin M., Snijders P.J., Schrijnemakers H.F., Voorhorst F.J., Rozendaal L., Nobbenhuis M.A., et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int. J. Cancer. 98:2002;590-595
32. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19
33. Wallin K.L., Wiklund F., Angstrom T., Bergman F., Stendahl U., Wadell G., et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med. 341:1999;1633-1638
34. Ylitalo N., Sorensen P., Josefsson A.M., Magnusson P.K., Andersen P.K., Ponten J., et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 355:2000;2194-2198